Ask AI
ProCE Banner Activity

Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026

Podcast Episodes

In this episode, experts discuss the rapidly evolving bladder cancer treatment landscape, including new options for BCG-unresponsive disease, emerging perioperative regimens, and the growing role of biomarkers and multidisciplinary care in guiding treatment decisions.

Released: March 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Ferring Pharmaceuticals Inc., and Merck Sharp & Dohme LLC.

AstraZeneca

Ferring Pharmaceuticals Inc.

Merck Sharp & Dohme, LLC

Target Audience

This activity has been designed to meet the educational needs of urologists, oncologists, and other healthcare professionals who care for patients with bladder cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess current and investigational strategies for the treatment of non–muscle-invasive bladder cancer and discuss with patients which approaches might benefit them

  • Implement optimal immunotherapy-based treatment for patients with muscle-invasive bladder cancer, focusing on recent data supporting bladder-sparing and perioperative approaches

  • Apply recent approvals and guideline-recommended strategies to improve outcomes in patients with metastatic bladder cancer in both the frontline and later-line settings

  • Assess available research findings and ongoing studies evaluating promising investigational agents and strategies for patients with non–muscle-invasive bladder cancer, muscle-invasive bladder cancer, and metastatic bladder cancer

Disclosure

Primary Author

Sam S. Chang, MD, MBA: consultant/advisor/speaker: CG Oncology, Ferring, Johnson & Johnson, Merck, Pacific Edge, Pfizer, Photocure, Prokarium, UroGen.

Matthew D. Galsky, MD: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Gilead, Janssen, Merck, Pfizer.